XBIO REPORT

Tag: FDA Approval

November 11, 2026

FDA Approves Pimjetmi (pimicotinib) for Tenosynovial Giant Cell Tumor (TGCT)

A New Treatment Option for Patients The U.S. Food and Drug Administration (FDA) has officially approved Pimjetmi (pimicotinib), a significant advancement for adult patients living with tenosynovial giant cell tumor (TGCT). This condition is a rare, non-malignant tumor that affects the synovium, bursae, and tendon sheaths, often causing severe pain, joint swelling, and significant functional…

FDA Acceptance

FDA Approval, oncology, pimicotinib, Pimjetmi, Tenosynovial Giant Cell Tumor, TGCT
November 10, 2026

FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention

WHIPPANY, N.J.– November 9, 2026 — Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with… Source: Read More

FDA Acceptance

Antiplatelet Therapy, asundexian, FDA Approval, stroke prevention, Sunharbo
November 9, 2026

A Breakthrough in Lung Cancer Treatment: FDA Approves Rybrevant + Lazertinib Combination

NYSE: $JNJ A New Frontier in Targeted Therapy In a significant development for oncology, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib. This treatment is specifically indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung…

FDA Acceptance

$JNJ, EGFR Mutation, FDA Approval, Johnson & Johnson, Non-Small Cell Lung Cancer, oncology, Rybrevant
November 1, 2026

FDA Approves Lucamzi: A New Biosimilar Option for Retinal Conditions

A New Milestone in Ophthalmology The landscape for treating serious eye conditions has expanded. The U.S. Food and Drug Administration (FDA) has officially approved Lucamzi (ranibizumab-blrz), a biosimilar to the well-known reference product, Lucentis. This approval marks an important step in providing healthcare providers and patients with additional treatment alternatives for managing vision-related diseases. What…

FDA Acceptance

Biosimilar, FDA Approval, Lucamzi, Lucentis, ranibizumab-blrz
November 1, 2026

FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 11-01-2026 TO 11-07-2026

I’m excited to announce the release of my latest FREE bio tech stock catalyst report for the upcoming week. This new FREE stock report highlights bio tech companies that have an important upcoming event and an expected price move of 20 percent up or down ($ +/- 20%) to help you make informed market decisions.…

FREE Weekly Stock Catalyst Report

$AKTX, $IMUX, $INO, $IVA, biopharmaceutical, FDA Approval, pr-newswire, press-releases
October 31, 2026

New Treatment Option Approved: Ilumya (tildrakizumab-asmn) for Psoriatic Arthritis

A New Milestone for Psoriatic Arthritis Care The U.S. Food and Drug Administration (FDA) has officially approved Ilumya (tildrakizumab-asmn) for the treatment of adults living with active psoriatic arthritis (PsA). This approval provides a significant new therapeutic option for patients managing this complex, inflammatory condition. Understanding Ilumya Ilumya is a humanized interleukin-23 (IL-23) p19 subunit…

FDA Acceptance

FDA Approval, IL-23 inhibitor, Ilumya, Psoriatic Arthritis, tildrakizumab-asmn
October 31, 2026

A Breakthrough in Rare Disease: FDA Grants Accelerated Approval to Voceryq

NASDAQ: $INO New Hope for Patients with Dystrophic Epidermolysis Bullosa The medical community is celebrating a significant milestone in genetic medicine. The U.S. Food and Drug Administration (FDA) has officially granted accelerated approval to Voceryq (beremagene geperpavec-svdt), a transformative gene therapy designed to treat wounds in patients aged 6 months and older with dystrophic epidermolysis…

FDA Acceptance

$INO, Dystrophic Epidermolysis Bullosa, FDA Approval, gene therapy, Inovio Pharmaceuticals Inc, Rare Diseases, Voceryq
October 29, 2026

A Breakthrough for IgA Nephropathy: Ultomiris Receives FDA Accelerated Approval

A New Option for Kidney Health The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab-cwvz) for the treatment of adults with immunoglobulin A nephropathy (IgAN). This milestone marks Ultomiris as the first and only C5 complement inhibitor indicated to reduce proteinuria in patients with this progressive kidney disease. Understanding the…

FDA Acceptance

C5 complement inhibitor, FDA Approval, IgA nephropathy, Proteinuria, Ultomiris
October 29, 2026

New Treatment Option for HAE: BioCryst Receives FDA Approval for Orladeyo Oral Pellets

NASDAQ: $BCRX A Milestone for HAE Patients BioCryst Pharmaceuticals has reached a significant milestone in the management of Hereditary Angioedema (HAE). The U.S. Food and Drug Administration (FDA) has officially approved Orladeyo (berotralstat) 150 mg oral pellets. This approval provides a new, convenient treatment option for adults and adolescents aged 12 years and older looking…

FDA Acceptance

$BCRX, BioCryst, FDA Approval, Hereditary Angioedema, Orladeyo, Rare Diseases
October 29, 2026

New Treatment Milestone: FDA Approves Subcutaneous Induction Regimen for Skyrizi

NYSE: $ABBV A New Step Forward for Ulcerative Colitis Treatment The landscape of treatment for adults living with moderately to severely active ulcerative colitis (UC) has officially expanded. The FDA has approved a new subcutaneous induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa), providing patients with a new, flexible option for managing their condition. What This Approval…

FDA Acceptance

$ABBV, AbbVie, FDA Approval, Risankizumab, Skyrizi, Ulcerative Colitis
October 28, 2026

A New Era for Diabetes Care: FDA Approves Awiqli for Children and Adolescents

NYSE: $NVO A Breakthrough in Insulin Therapy Managing type 1 and type 2 diabetes has long required the demanding routine of daily insulin injections. However, a significant advancement has arrived. The FDA has officially approved Awiqli (insulin icodec), marking it as the first and only once-weekly basal insulin for children and adolescents aged 10 years…

FDA Acceptance

$NVO, adolescents, Awiqli, children, diabetes, FDA Approval, icodec, Insulin, Novo Nordisk
October 28, 2026

Pfizer’s Talzenna Plus Xtandi FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

NYSE: $PFE NEW YORK–(BUSINESS WIRE) October 26, 2026 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of… Source: Read More

FDA Acceptance

$PFE, FDA Approval, Metastatic, pfizer, Prostate Cancer, Talzenna, Xtandi
October 23, 2026

New Treatment Option: FDA Approves Subcutaneous Induction for Skyrizi in Crohn’s Disease

NYSE: $ABBV A New Milestone in Crohn’s Disease Management For adults living with moderately to severely active Crohn’s disease, there is a significant new development in treatment accessibility. The U.S. Food and Drug Administration (FDA) has officially approved a subcutaneous (SC) induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa). What This Means for Patients Previously, patients often…

Announcements

$ABBV, AbbVie, Crohns Disease, FDA Approval, pr-newswire, Risankizumab, Skyrizi
October 22, 2026

Viatris Receives U.S. FDA Approval for Ryzumvi for the Treatment of Presbyopia

NASDAQ: $VTRS PITTSBURGH, Oct. 16, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of… Source: Read More

FDA Acceptance

$VTRS, FDA Approval, Presbyopia, Ryzumvi, Viatris Inc
October 21, 2026

Clearer Eyes Ahead: FDA Approves Upneeq (Apraclonidine) for Eye Redness

NYSE: $ALC A New Solution for Eye Redness Dealing with persistent eye redness can be frustrating, often affecting both comfort and appearance. Recently, the FDA provided a new option for patients by approving Upneeq (apraclonidine hydrochloride ophthalmic solution), a prescription eye drop designed to address this common concern. What You Should Know About Upneeq Upneeq…

FDA Acceptance

$ALC, Apraclonidine, Eye Redness, FDA Approval, Ophthalmic Solution, Upneeq
October 21, 2026

New Treatment Option: Cosette Pharmaceuticals Receives FDA Approval for Evoxac Oral Solution

A New Milestone in Dry Mouth Treatment Patients suffering from the symptoms of Sjogren’s syndrome now have a new way to manage their condition. Cosette Pharmaceuticals, Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted approval for Evoxac (cevimeline HCl) oral solution (15 mg/5 mL). This approval marks an important…

FDA Acceptance

Cevimeline HCl, Cosette Pharmaceuticals, Evoxac, FDA Approval, Sjögren’s syndrome
October 21, 2026

New Hope for Chronic Hepatitis B: Understanding the FDA Approval of Hepcludex (bepirovirsen)

NYSE: $GSK A Significant Milestone in Liver Health The landscape of chronic hepatitis B (CHB) treatment is evolving. Recently, the FDA reached a significant decision regarding Hepcludex (bepirovirsen), providing new options for patients managing this complex viral infection. This development marks a noteworthy step forward in therapeutic approaches for those living with chronic liver disease.…

FDA Acceptance

$GSK, Bepirovirsen, Chronic Liver Disease, FDA Approval, Hepatitis B, Hepcludex
October 20, 2026

UCB Announces U.S. FDA Approval for Zilbrysq (zilucoplan) Autoinjector Self-administration for Adults Living with Generalized Myasthenia Gravis

Brussels, Belgium and Atlanta, Georgia – October 16, 2026 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered… Source: Read More

FDA Acceptance

autoinjector, FDA Approval, Generalized Myasthenia Gravis, UCB, Zilbrysq, zilucoplan
October 20, 2026

Jemperli (dostarlimab-gxly) Approved in US as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

NYSE: $GSK Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite… Source: Read More

FDA Acceptance

$GSK, dostarlimab-gxly, FDA Approval, immunotherapy, Jemperli, MSI-H/dMMR, rectal cancer
October 19, 2026

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

South San Francisco, CA — October 15, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of… Source: Read More

FDA Acceptance

Enspryng, FDA Approval, Genentech, IL-6R, Subcutaneous, TED, thyroid eye disease
October 16, 2026

FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder

September 29, 2026 — Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Lamlique&trade… Source: Read More

FDA Acceptance

Azurity Pharmaceuticals, Bipolar Disorder, FDA Approval, Lamlique, lamotrigine, seizures
October 15, 2026

New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment

NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…

FDA Acceptance

$IBRX, Anktiva, bladder cancer, FDA Approval, ImmunityBio, Inc., immunotherapy, NMIBC, nogapendekin alfa inbakicept-pmln
October 14, 2026

FDA Approves Tecentriq Combination as Adjuvant Therapy for Specific Colon Cancer

A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…

FDA Acceptance

Adjuvant Therapy, Colon Cancer, FDA Approval, Genentech, Tecentriq
October 14, 2026

FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia

PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has… Source: Read More

FDA Acceptance

FDA Approval, Injection, olanzapine, Schizophrenia, Subcutaneous, Weltruza
October 13, 2026

A New Frontier in Treatment: FDA Approves Hovilpri (pritelivir) for Resistant HSV

A Breakthrough for Immunocompromised Patients For individuals living with immunocompromised conditions, managing mucocutaneous herpes simplex virus (HSV) can be a persistent and painful challenge. Recently, the medical community reached a significant milestone as the FDA approved Hovilpri (pritelivir), offering a new therapeutic option for those who struggle with lesions that do not respond to conventional…

FDA Acceptance

acyclovir, elicase-primase complex, FDA Approval, herpes simplex virus, Hovilpri, HSV, pritelivir